[1] GONG L, PAN LY, LIU Y, et al.Detection and evaluation of post-marketing safety alert signals for human papillomavirus 9-valent vaccine based on US vaccine adverse event reporting system (VAERS)[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2019, 16(8): 478-486. [2] MOORE NF, BEGAUD TB.The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions[J]. Pharmacoepidemiol Drug Saf, 2005, 14(4): 285-286. [3] BATE A, EVANS SJ.Quantitative signal detection using spontaneous ADR reporting[J]. Pharmacoepidemiol Drug Safety, 2009, 18(6): 427-436. [4] LIANG B, ZHOU C.Clinical research and development of new drugs-analysis of the principle of safety evaluation[J]. Journal of Pharmaceutical Epidemiology(药物流行病学杂志),2013, 22(1): 35-39. [5] LI QF, LIU H, ZHANG DD, et al.Analysis and suggestions on risk of ribavirin in children[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(2): 83-89. [6] LIU XT, WANG JX.Related mechanisms and countermeasures of hemolytic anemia caused by ribavirin[J]. Chinese Hepatology(肝脏), 2012, 17(11): 814-817. [7] KEPPEKE GD, CALISE SJ, CHAN EK, et al.Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-alpha/ribavirin therapy[J]. World J Gastroenterol, 2016, 22(6): 1966-1974. [8] HUNYADY B, KOVACS B, BATTYANI Z.Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection[J]. Orv Hetil, 2011, 152(50): 1997-2009. [9] KASTURI KS, MUMMADI RR, SOOD GK.Neutropenic enterocolitis: An unusual complication of HCV combination therapy with PEG-IFN and ribavirin[J]. Eur J Intern Med, 2008, 19(5): 372-373. [10] JACKOWIAK E, SHAH N, CHEN H, et al.A case of immune reconstitution syndrome complicating progressive multifocal leukoencephalopathy after kidney transplant: clinical, pathological, and radiographic features[J]. Transpl Infect Dis, 2019, 21(5): e13162-e13168. [11] CALZA L, TRAPANI F, SALVADORI C, et al.Incidence of renal toxicity in HIV-infected, antiretroviral-naive patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir[J]. Scand J Infect Dis, 2013, 45(2): 147-154. [12] MANON VAN DER LRS, EMILE S. Pharmac-okinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients[J]. Antiviral Therapy, 2007, 12(7): 1127-1132. [13] Society European AIDS Clinical. 2019 European AIDS clinical society guidelines version 10.0 [EB/OL]. (2019-11-08) [2020-03-02]. http://guide.medlive.cn/guideline/19262. [14] YUSUF IH, SHARMA S, LUQMANI R, et al.Hydroxychloroquine retinopathy[J]. Eye (Lond), 2017, 31(6): 828-845. [15] CHATRE C, ROUBILLE F, VERNHET H, et al.Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature[J]. Drug Saf, 2018, 41(10): 919-923. |